Printer Friendly
The Free Library
14,488,142 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Eisai Launches New OTC Antituissive Expectorant ASTHPHYLLIN S Tablets.


Tokyo, Japan, Aug 23, 2005 - (JCNN JCNN Japan Corporate News Network ) - Eisai announced on August 22 that it began marketing ASTHPHYLLIN S, an over-the-counter expectorant expectorant /ex·pec·to·rant/ (ek-spek´ter-ant)
1. promoting expectoration.

2. an agent that promotes expectoration.
 drug, on the same day.

Based on ASTHPHYLLIN, the company's proprietary ethical drug indicated for asthma, the new product contains diprophylline, dl-methylephedrine hydrochloride, noscapine, and diphenhydramine hydrochloride, and helps alleviate coughing and loosen phlegm phlegm

humor effecting temperament of sluggishness. [Medieval Physiology: Hall, 130]

See : Laziness
.

The drug comes in two sizes, 60- and 120-tablet bottles, which retail for 1,344 yen ($12) and 2,394 yen ($21), respectively.

Source: JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
 http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Aug 27, 2005
Words:93
Previous Article:Suntory International, Blavod Extreme Spirits Establish Joint Venture Company in US.
Next Article:Pfizer Japan Releases OTC Topical Drug.



Related Articles
The home medicine cabinet: appropriate management of the family medicine cabinet is mostly just good, common sense.
Eisai Files Application Seeking Additional Indication for ARICEPT in US.
Eisai to Distribute Actonel Osteoporosis Treatment for Ajinomoto.
Eisai Establishes European Strategic Business Hub in the U.K.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai Files Application Seeking Additional Indication for ARICEPT in Europe.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.
A Once-weekly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent, Was Approved.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles